VHL and renal cell carcinoma: To test if IFN-γ immunocytokines also induced RIP1-mediated necrotic death when combined with bortezomib, we pretreated (for 1h) RenCa and Caki-1 cells, as well as the additional pVHL-null human RCC cell lines 786-0 and HRC63, with a stable analog of the selective RIP1 kinase inhibitor Necrostatin-1 (Nec-1) [48], [49], before exposing these cells to the combination of IFN-γ immunocytokines and bortezomib.